National Council for Prescription Drug Programs indexing - billing unit
- Manufacturer
- National Council for Prescription Drug Programs
- Effective date
- 2012-07-24
- Label type
- Indexing - Billing Unit
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-05 02:08:31
Label at a glance#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0781-5190-92 | EA - Each | 0781-5190 | 80dd541d-c95e-484a-840e-cc4d38630cbc | 1 | 2012-07-24 |
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 0781-5190 | 0781-5190-92 |
Source Document#
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021342-001 | LEVO-T | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-002 | LEVO-T | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-003 | LEVO-T | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-004 | LEVO-T | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-005 | LEVO-T | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-006 | LEVO-T | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-007 | LEVO-T | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-008 | LEVO-T | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-009 | LEVO-T | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-010 | LEVO-T | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-011 | LEVO-T | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-012 | LEVO-T | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021342-001 | AB1 |
| N021342-001 | AB2 |
| N021342-001 | AB3 |
| N021342-002 | AB1 |
| N021342-002 | AB2 |
| N021342-002 | AB3 |
| N021342-003 | AB1 |
| N021342-003 | AB2 |
| N021342-003 | AB3 |
| N021342-004 | AB1 |
| N021342-004 | AB2 |
| N021342-004 | AB3 |
| N021342-005 | AB1 |
| N021342-005 | AB2 |
| N021342-005 | AB3 |
| N021342-006 | AB1 |
| N021342-006 | AB2 |
| N021342-006 | AB3 |
| N021342-007 | AB1 |
| N021342-007 | AB2 |
| N021342-007 | AB3 |
| N021342-008 | AB1 |
| N021342-008 | AB2 |
| N021342-008 | AB3 |
| N021342-009 | AB1 |
| N021342-009 | AB2 |
| N021342-009 | AB3 |
| N021342-010 | AB1 |
| N021342-010 | AB2 |
| N021342-010 | AB3 |
| N021342-011 | AB1 |
| N021342-011 | AB2 |
| N021342-011 | AB3 |
| N021342-012 | AB1 |
| N021342-012 | AB2 |
| N021342-012 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-005 | LEVO-T | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-006 | LEVO-T | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-007 | LEVO-T | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-008 | LEVO-T | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-009 | LEVO-T | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-010 | LEVO-T | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-011 | LEVO-T | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-012 | LEVO-T | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-005 | LEVO-T | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-006 | LEVO-T | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-007 | LEVO-T | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-008 | LEVO-T | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-009 | LEVO-T | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-010 | LEVO-T | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-011 | LEVO-T | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-012 | LEVO-T | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-005 | LEVO-T | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-006 | LEVO-T | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-007 | LEVO-T | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-008 | LEVO-T | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-009 | LEVO-T | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-010 | LEVO-T | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-011 | LEVO-T | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-012 | LEVO-T | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 011fe1cb6892… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-002 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-002 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-002 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-003 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-003 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-003 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-004 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-004 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-004 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-005 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-005 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-005 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-006 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-006 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-006 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-007 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-007 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-007 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-008 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-008 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-008 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-009 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-009 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-009 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-010 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-010 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-010 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-011 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-011 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-011 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-012 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-012 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-012 | AB3 | 3 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N021342-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021342-001 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021342-001 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021342-002 | AB1 | 1 | 84e616aacf4f… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N021342-001 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-002 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-003 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-004 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-005 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-006 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-007 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-008 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-009 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-010 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-011 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-001 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-002 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-003 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-004 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-005 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-006 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-007 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-008 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-009 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-010 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-011 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-001 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-002 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-003 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-004 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-005 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-006 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-007 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-008 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-009 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-010 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-011 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-001 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-002 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-003 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-004 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-005 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-006 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-007 | 6399101 | 2020-03-30 | 3f01610625f2… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.